Comparison of amyloid PET acquired through standardized and unstandardized protocols

IF 11.1 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-09-22 DOI:10.1002/alz.70697

Karly A. Cody, Andrzej Sokolowski, Lucah Medina Guerra, Philip S. Insel, William J. Jagust, Theresa M. Harrison, Elizabeth C. Mormino

{"title":"Comparison of amyloid PET acquired through standardized and unstandardized protocols","authors":"Karly A. Cody, Andrzej Sokolowski, Lucah Medina Guerra, Philip S. Insel, William J. Jagust, Theresa M. Harrison, Elizabeth C. Mormino","doi":"10.1002/alz.70697","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Amyloid positron emission tomography (PET) scans collected by Alzheimer's Disease Research Centers (ADRCs) include site-specific “mixed protocols” and, since 2021, standardized protocols through the Standardized, Centralized AD/ADRD Neuroimaging initiative. We compared amyloid PET from cohorts using unstandardized versus standardized pre-processing protocols.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Across cohorts, amyloid measured in Centiloids (CLs) was derived from 18F-florbetapir (FBP), 18F-florbetaben (FBB), 11C-Pittsburgh compound B (PIB), and 18F-NAV4694 (NAV) scans using identical magnetic resonance imaging–free post-processing pipelines. We evaluated CL distributions across cohorts and tracers using Gaussian mixture models (GMMs).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Within each tracer, GMM-derived amyloid negative (A–) CL distributions were similar across cohorts. PIB and NAV showed lower CL variability in the A– range than FBP and FBB.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Consistent post-processing yielded comparable A– distributions within tracer across cohorts with heterogeneous pre-processing protocols, supporting future ADRC PET data integration. Reduced variability in A– classes for PIB and NAV suggest that lower positivity thresholds may be appropriate.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Alzheimer's Disease Research Center (ADRC) amyloid positron emission tomography (PET) includes unstandardized and standardized pre-processing.</li>\n \n <li>With consistent post-processing, amyloid-negative (A–) Centiloids (CLs) were similar despite variable pre-processing.</li>\n \n <li>CLs from 11C-Pittsburgh compound B and 18F-NAV4694 were less variable than 18F-florbetaben and 18F-florbetapir.</li>\n \n <li>Similar A– CLs across variable pre-processing supports combining ADRC amyloid PET.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 9","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70697","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70697","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Amyloid positron emission tomography (PET) scans collected by Alzheimer's Disease Research Centers (ADRCs) include site-specific “mixed protocols” and, since 2021, standardized protocols through the Standardized, Centralized AD/ADRD Neuroimaging initiative. We compared amyloid PET from cohorts using unstandardized versus standardized pre-processing protocols.

METHODS

Across cohorts, amyloid measured in Centiloids (CLs) was derived from 18F-florbetapir (FBP), 18F-florbetaben (FBB), 11C-Pittsburgh compound B (PIB), and 18F-NAV4694 (NAV) scans using identical magnetic resonance imaging–free post-processing pipelines. We evaluated CL distributions across cohorts and tracers using Gaussian mixture models (GMMs).

RESULTS

Within each tracer, GMM-derived amyloid negative (A–) CL distributions were similar across cohorts. PIB and NAV showed lower CL variability in the A– range than FBP and FBB.

DISCUSSION

Consistent post-processing yielded comparable A– distributions within tracer across cohorts with heterogeneous pre-processing protocols, supporting future ADRC PET data integration. Reduced variability in A– classes for PIB and NAV suggest that lower positivity thresholds may be appropriate.

Highlights

Alzheimer's Disease Research Center (ADRC) amyloid positron emission tomography (PET) includes unstandardized and standardized pre-processing.
With consistent post-processing, amyloid-negative (A–) Centiloids (CLs) were similar despite variable pre-processing.
CLs from 11C-Pittsburgh compound B and 18F-NAV4694 were less variable than 18F-florbetaben and 18F-florbetapir.
Similar A– CLs across variable pre-processing supports combining ADRC amyloid PET.

Abstract Image

查看原文本刊更多论文

通过标准化和非标准化方案获得的淀粉样PET的比较

由阿尔茨海默病研究中心（adrc）收集的淀粉样蛋白正电子发射断层扫描（PET）扫描包括特定部位的“混合方案”，以及自2021年以来通过标准化，集中式AD/ADRD神经成像计划的标准化方案。我们比较了使用非标准化和标准化预处理方案的队列中的淀粉样PET。方法：在整个队列中，在Centiloids （CLs）中测量的淀粉样蛋白来自18F-florbetapir (FBP), 18F-florbetaben (FBB)， 11C-Pittsburgh化合物B （PIB）和18F-NAV4694 （NAV）扫描，使用相同的免磁共振成像后处理管道。我们使用高斯混合模型（gmm）评估了跨队列和示踪剂的CL分布。结果在每种示踪剂中，gmm衍生的淀粉样蛋白阴性（A -） CL分布在队列中相似。PIB和NAV在A范围内的CL变异性低于FBP和FBB。一致的后处理产生了具有异构预处理协议的示踪剂中可比较的A -分布，支持未来ADRC PET数据集成。PIB和NAV A级变异性的降低表明降低阳性阈值可能是合适的。阿尔茨海默病研究中心（ADRC）淀粉样正电子发射断层扫描（PET）包括非标准化和标准化预处理。经过一致的后处理，尽管预处理不同，淀粉样蛋白阴性（A -） Centiloids （CLs）相似。与18F-florbetaben和18F-florbetapir相比，11C-Pittsburgh化合物B和18F-NAV4694的CLs变化较小。类似的A - cl跨变量预处理支持结合ADRC淀粉样PET。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.